RxDoctor Payments Data

Asghar Anwar, MD

Internal Medicine · Poughkeepsie, NYNPI 1174537401

Payments from drug & device makers

$3,197in general payments, 2019–2025

Across 169 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$742
  • AstraZeneca$660
  • Novo Nordisk$620
  • Boehringer Ingelheim$346
  • GSK$220
  • Pfizer$167
  • plus $442 from 9 others

What the payments were for

  • Food & beverage$3,197100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,197 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$155,883
Medicare patients
516
Services billed
2,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin178$219,534
FarxigaDapagliflozin Propanediol111$124,189
OzempicSemaglutide90$122,719
EliquisApixaban105$118,376
JanuviaSitagliptin Phosphate88$81,511
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$80,178
MounjaroTirzepatide59$67,812
XareltoRivaroxaban50$65,572
TrulicityDulaglutide54$65,264
EntrestoSacubitril/Valsartan25$26,183
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$25,725
Breo ElliptaFluticasone/Vilanterol44$20,061
MyrbetriqMirabegron29$19,418
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$17,438
JanumetSitagliptin Phos/Metformin Hcl18$15,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$346$226,273189 claims
AstraZenecaFarxiga, Breztri Aerosphere$660$149,914138 claims
Lilly USA, LLCMounjaro, Trulicity$742$133,076113 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$220$129,338176 claims
Novo NordiskOzempic$620$122,71990 claims
PfizerEliquis$167$118,376105 claims
Johnson & JohnsonXarelto$56$65,57250 claims
NovartisEntresto$17$26,18325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →